Aptus will use the finance to expand commercialization of its HeliFX Aortic Securement system in the US and Europe.
The company will also use the proceeds to further develop HeliFX product offerings to fulfill unmet needs in the treatment of aortic aneurysms (AAA).
In addition, the company plans to conduct a clinical trial of the Fortevo AAA Endograft system in support of filing for premarket approval with the US FDA as well as expand the Fortevo system in key European centers.
The financing round was led by Synergy Life Science Partners, which is joined in the current round by Aptus’ existing investors US Venture Partners and Longitude Capital Management.
Aptus board chairman and US Venture Partners partner Alan Kaganov said, "We welcome Synergy Life Science Partners to Aptus and collectively, we will continue to support the company’s endograft and fixation platforms to ensure that both patients and physicians have access to a new standard in long-term durability in EVAR."
